Name: Reyhaneh Manafi-Farid

Academic rank: Assistant Professor

Department: Nuclear Medicine

Service location(s)/ hospital(s): Research Center for Nuclear Medicine, Dr. Shariati Hospital

Field of activity:
Nuclear Medicine
PET/CT
SPECT/CT
Radionuclide Therapy
Thyroid Disorders and Malignancies

Education:
2015-2019: Nuclear Medicine Specialist, Tehran University of Medical Sciences, Iran
2007-2015: Doctor of Medicine, Tabriz University of Medical Sciences, Iran

Experience:
2020-Present: Deputy of Treatment in Nuclear Medicine Department
2019-Present: Administer of Residency Education
2019-Present: Attending Physician in Nuclear Medicine Department, Dr. Shariati Hospital
2018: Research Fellowship, PET/CT Center, Orednklinikum, Linz, Austria

Memberships:
2020-Present: Iranian Association of Nuclear Medicine
2000-2007: National Organization for Development of Exceptional Talents

Publications:

1. Saidi, B., Fallahi, B., **Manafi-Farid, R.,** Fard-Esfahani, A. and Eftekhari, M., 2022. 68Ga-DOTATATE Uptake in an Intraosseous Hemangioma, as a Potential Cause of False-Positive PET/CT Finding, Simulating Tumoral Involvement. *Clinical nuclear medicine*.

2. Mirshahvalad, S.A., Chavoshi, M., Kashkouli, M.B., Fallahi, B., Emami-Ardakani, A. **and Manafi-Farid, R**., 2022. Diagnostic value of lacrimal scintigraphy in the evaluation of lacrimal drainage system obstruction: a systematic review and meta-analysis. *Nuclear Medicine Communications*, pp.10-1097.

3. Emami-Ardekani, A., Ghorbani-Nik, F., Karamzade-Ziarati, N., **Manafi-Farid, R.,** Fard-Esfahani, A., Fallahi, B., Beiki, D., Salehi, Y., Eftekhari, M. 2022. Impact of TSH Stimulation on 2-[18F]FDG PET/CT Results in Patients with Papillary Thyroid Carcinoma Presented with Elevated Serum Thyroglobulin Level and Negative Diagnostic Iodine-131 Whole-Body Scan. *Iranian Journal of Nuclear Medicine.*

4. Haghighi, F., **Manafi-Farid, R**., Emami-Ardekani, A. and Beiki, D., 2022. Disseminated thoracoabdominal splenosis mimicking metastatic disease: A case of colorectal cancer. *Iranian Journal of Nuclear Medicine*, *30*(1), pp.72-75.

5. Schweighofer-Zwink, G., **Manafi-Farid, R.,** Kölblinger, P., Hehenwarter, L., Harsini, S., Pirich, C. and Beheshti, M., 2021. Prognostic value of 2-[18F] FDG PET-CT in metastatic melanoma patients receiving immunotherapy. *European Journal of Radiology*, p.110107.

6. Seyyedinia, S., Karamzade-Ziarati, N., Fard-Esfahani, **A., Manafi-Farid, R.** and Eftekhari, M., 2021. [18F] FDG PET/CT in a case of recurrent primary cardiac osteosarcoma. *Iranian Journal of Nuclear Medicine*, pp.1-5.

7. **Manafi-Farid, R.,** Ranjbar, S., Jamshidi Araghi, Z., Pilz, J., Schweighofer-Zwink, G., Pirich, C. and Beheshti, M., 2021. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. *Cancers*, *13*(21), p.5360.

8. Mousavi, S.A. Rostami, T., Hedayati Asl, A.A., **Manafi-Farid, R.**, Kiumarsi, A., 2021, June. Reduced-Intensity Unmanipulated Haploidentical Stem Cell Transplantation for Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplantation. In *BONE MARROW TRANSPLANTATION* (Vol. 56, No. SUPPL 1, pp. 214-215). CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND: SPRINGERNATURE.

9. **Manafi-Farid, R.,** Karamzade-Ziarati, N., Vali, R., Mottaghy, F.M. and Beheshti, M., 2021. 2-[18F] FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease. *Methods*, *188*, pp.84-97.

10. **Manafi-Farid, R.**, Harsini, S., Saidi, B., Ahmadzadehfar, H., Herrmann, K., Briganti, A., Walz, J. and Beheshti, M., 2021. Factors predicting biochemical response and survival benefits following radioligand therapy with [177 Lu] Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. *European Journal of Nuclear Medicine and Molecular Imaging*, pp.1-14.

11. Beheshti, M., **Manafi-Farid, R.**, Geinitz, H., Vali, R., Loidl, W., Mottaghy, F.M. and Langsteger, W., 2020. Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: A prospective study of 135 patients. *Journal of Nuclear Medicine*, *61*(10), pp.1484-1490.

12. **Manafi-Farid, R.**, Kupferthaler, A., Wundsam, H., Gruber, G., Vali, R., Venhoda, C., Track, C., Beheshti, A., Langsteger, W., Geinitz, H. and Beheshti, M., 2020. Additional value of 2-[18F] FDG PET/CT comparing to MRI in treatment approach of anal cancer patients. *Journal of clinical medicine*, *9*(9), p.2715.

13. **Manafi-Farid, R.**, Masoumi, F., Divband, G., Saidi, B., Ataeinia, B., Hertel, F., Schweighofer-Zwink, G., Morgenroth, A. and Beheshti, M., 2020. Targeted palliative radionuclide therapy for metastatic bone pain. *Journal of Clinical Medicine*, *9*(8), p.2622.

14. Beheshti, M., **Manafi-Farid, R.**, Rezaee, A. and Langsteger, W., 2020. PET/CT and PET/MRI, normal variations, and artifacts. In *Clinical Nuclear Medicine* (pp. 549-584). Springer, Cham.

15. Beheshti, M., **Manafi-Farid, R.**, Mottaghy, F., Loidl, W., Geinitz, H. and Langsteger, W., 2019. Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA< 1 ng/ml: a prospective study of 105 cases.

16. Beheshti, M., **Manafi-Farid, R.**, Beheshti, A., Wundsam, H., Mottaghy, F., Geinitz, H. and Langsteger, W., 2019. Impact of 18F-FDG PET/CT comparing to MRI in primary staging and treatment approach of anal cancer.

17. Karamzade-Ziarati, N., **Manafi-Farid, R.,** Ataeinia, B., Langsteger, W., Pirich, C., Mottaghy, F.M. and Beheshti, M., 2019. Molecular imaging of bone metastases using tumor-targeted tracers. *The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of..*, *63*(2), pp.136-149.

18. Fallahi, B., **Manafi-Farid, R.**, Eftekhari, M., Fard-Esfahani, A., Emami-Ardekani, A., Geramifar, P., Akhlaghi, M., Taheri, A.P.H. and Beiki, D., 2019. Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors. *Asia Oceania Journal of Nuclear Medicine and Biology*, *7*(2), p.129.

19. **Manafi-Farid, R.**, Ayati, N., Eftekhari, M., Fallahi, B. and Masoumi, F., 2019. A rare presentation of colorectal cancer with unusual progressive intramuscular and subcutaneous metastatic spread. *Asia Oceania Journal of Nuclear Medicine and Biology*, *7*(1), p.89.

20. Manafi-Farid, R. et al. "Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors. Asia Oceania Journal of Nuclear Medicine and Biology". *Thesis for nuclear medicine specialty*. (2019).

21. Manafi-Farid, R. et al. "Awareness and knowledge about Human Papilloma Virus among patients attending to public and private clinics and its relationship to socio-demographic characteristics". *MD Thesis*. (2015).

22. Manafi-Farid, R. "Educational pamphlet on Human Papilloma Virus". *Gynecology Department of Tabriz University of Medical Sciences*. (2013).

23. Manafi-Farid, R. "Educational pamphlet on Fever and Convulsion". *Pediatric Department of Tabriz University of Medical Sciences. (2011).*

Languages:
Native: Turkish (Azeri), Persian
Proficient in reading, writing and comprehension: English (TOEFL score: 102)

Awards & honors:
The best oral presentation of young participants: 23rd Annual Iranian Nuclear Medicine Society Congress (Oral presentation – PET/CT in Head and Neck Cancers)
The best oral presentation of young participants: 22th Annual Iranian Nuclear Medicine Society Congress (Oral presentation- Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 105 cases)

رزومه

نام و نام خانوادگی: ریحانه منافی فرید

مرتبه علمی: استادیار

گروه آموزشی: پزشکی هسته ای

مکان های ارائه خدمت یا بیمارستان ها: مرکز تحقیقات پزشکی هسته ای، بیمارستان دکتر شریعتی

زمینه های فعالیت: پزشکی هسته ای (PET/CT, SPECT/CT، Radinuclide Therapy، سرطان و بیماری های تیروئید)

سوابق تحصیلی:
1394 پزشکی عمومی، دانشگاه علوم پزشکی تبریز
1398 تخصص پزشکی هسته ای، دانشگاه علوم پزشکی تهران

تجربیات:
1397: فلوشیپ تحقیقاتی، لینز، اتریش
1398 تا کنون: متخصص پزشکی هسته ای در بیمارستان شریعتی

عضویت ها:
انجمن پزشکی هسته ای ایران

انتشارات:

1. Saidi, B., Fallahi, B., **Manafi-Farid, R.,** Fard-Esfahani, A. and Eftekhari, M., 2022. 68Ga-DOTATATE Uptake in an Intraosseous Hemangioma, as a Potential Cause of False-Positive PET/CT Finding, Simulating Tumoral Involvement. *Clinical nuclear medicine*.
2. Mirshahvalad, S.A., Chavoshi, M., Kashkouli, M.B., Fallahi, B., Emami-Ardakani, A. **and Manafi-Farid, R**., 2022. Diagnostic value of lacrimal scintigraphy in the evaluation of lacrimal drainage system obstruction: a systematic review and meta-analysis. *Nuclear Medicine Communications*, pp.10-1097.
3. Emami-Ardekani, A., Ghorbani-Nik, F., Karamzade-Ziarati, N., **Manafi-Farid, R.,** Fard-Esfahani, A., Fallahi, B., Beiki, D., Salehi, Y., Eftekhari, M. 2022. Impact of TSH Stimulation on 2-[18F]FDG PET/CT Results in Patients with Papillary Thyroid Carcinoma Presented with Elevated Serum Thyroglobulin Level and Negative Diagnostic Iodine-131 Whole-Body Scan. *Iranian Journal of Nuclear Medicine.*
4. Haghighi, F., **Manafi-Farid, R**., Emami-Ardekani, A. and Beiki, D., 2022. Disseminated thoracoabdominal splenosis mimicking metastatic disease: A case of colorectal cancer. *Iranian Journal of Nuclear Medicine*, *30*(1), pp.72-75.
5. Schweighofer-Zwink, G., **Manafi-Farid, R.,** Kölblinger, P., Hehenwarter, L., Harsini, S., Pirich, C. and Beheshti, M., 2021. Prognostic value of 2-[18F] FDG PET-CT in metastatic melanoma patients receiving immunotherapy. *European Journal of Radiology*, p.110107.
6. Seyyedinia, S., Karamzade-Ziarati, N., Fard-Esfahani, **A., Manafi-Farid, R.** and Eftekhari, M., 2021. [18F] FDG PET/CT in a case of recurrent primary cardiac osteosarcoma. *Iranian Journal of Nuclear Medicine*, pp.1-5.
7. **Manafi-Farid, R.,** Ranjbar, S., Jamshidi Araghi, Z., Pilz, J., Schweighofer-Zwink, G., Pirich, C. and Beheshti, M., 2021. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. *Cancers*, *13*(21), p.5360.

8. Mousavi, S.A. Rostami, T., Hedayati Asl, A.A., **Manafi-Farid, R.**, Kiumarsi, A., 2021, June. Reduced-Intensity Unmanipulated Haploidentical Stem Cell Transplantation for Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplantation. In *BONE MARROW TRANSPLANTATION* (Vol. 56, No. SUPPL 1, pp. 214-215). CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND: SPRINGERNATURE.
9. **Manafi-Farid, R.,** Karamzade-Ziarati, N., Vali, R., Mottaghy, F.M. and Beheshti, M., 2021. 2-[18F] FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease. *Methods*, *188*, pp.84-97.
10. **Manafi-Farid, R.**, Harsini, S., Saidi, B., Ahmadzadehfar, H., Herrmann, K., Briganti, A., Walz, J. and Beheshti, M., 2021. Factors predicting biochemical response and survival benefits following radioligand therapy with [177 Lu] Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. *European Journal of Nuclear Medicine and Molecular Imaging*, pp.1-14.
11. Beheshti, M., **Manafi-Farid, R.**, Geinitz, H., Vali, R., Loidl, W., Mottaghy, F.M. and Langsteger, W., 2020. Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: A prospective study of 135 patients. *Journal of Nuclear Medicine*, *61*(10), pp.1484-1490.
12. **Manafi-Farid, R.**, Kupferthaler, A., Wundsam, H., Gruber, G., Vali, R., Venhoda, C., Track, C., Beheshti, A., Langsteger, W., Geinitz, H. and Beheshti, M., 2020. Additional value of 2-[18F] FDG PET/CT comparing to MRI in treatment approach of anal cancer patients. *Journal of clinical medicine*, *9*(9), p.2715.
13. **Manafi-Farid, R.**, Masoumi, F., Divband, G., Saidi, B., Ataeinia, B., Hertel, F., Schweighofer-Zwink, G., Morgenroth, A. and Beheshti, M., 2020. Targeted palliative radionuclide therapy for metastatic bone pain. *Journal of Clinical Medicine*, *9*(8), p.2622.
14. Beheshti, M., **Manafi-Farid, R.**, Rezaee, A. and Langsteger, W., 2020. PET/CT and PET/MRI, normal variations, and artifacts. In *Clinical Nuclear Medicine* (pp. 549-584). Springer, Cham.
15. Beheshti, M., **Manafi-Farid, R.**, Mottaghy, F., Loidl, W., Geinitz, H. and Langsteger, W., 2019. Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA< 1 ng/ml: a prospective study of 105 cases.
16. Beheshti, M., **Manafi-Farid, R.**, Beheshti, A., Wundsam, H., Mottaghy, F., Geinitz, H. and Langsteger, W., 2019. Impact of 18F-FDG PET/CT comparing to MRI in primary staging and treatment approach of anal cancer.
17. Karamzade-Ziarati, N., **Manafi-Farid, R.,** Ataeinia, B., Langsteger, W., Pirich, C., Mottaghy, F.M. and Beheshti, M., 2019. Molecular imaging of bone metastases using tumor-targeted tracers. *The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of..*, *63*(2), pp.136-149.
18. Fallahi, B., **Manafi-Farid, R.**, Eftekhari, M., Fard-Esfahani, A., Emami-Ardekani, A., Geramifar, P., Akhlaghi, M., Taheri, A.P.H. and Beiki, D., 2019. Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors. *Asia Oceania Journal of Nuclear Medicine and Biology*, *7*(2), p.129.
19. **Manafi-Farid, R.**, Ayati, N., Eftekhari, M., Fallahi, B. and Masoumi, F., 2019. A rare presentation of colorectal cancer with unusual progressive intramuscular and subcutaneous metastatic spread. *Asia Oceania Journal of Nuclear Medicine and Biology*, *7*(1), p.89.

20. **Manafi-Farid, R.** et al. “Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors. Asia Oceania Journal of Nuclear Medicine and Biology”. *Thesis for nuclear medicine specialty*. (2019).
21. **Manafi-Farid, R.** et al. “Awareness and knowledge about Human Papilloma Virus among patients attending to public and private clinics and its relationship to socio-demographic characteristics”. *MD Thesis*. (2015).
22. **Manafi-Farid, R.** “Educational pamphlet on Human Papilloma Virus”. *Gynecology Department of Tabriz University of Medical Sciences*. (2013).
23. **Manafi-Farid, R.** “Educational pamphlet on Fever and Convulsion”. *Pediatric Department of Tabriz University of Medical Sciences. (2011).*

زبان ها:
ترکی آذری، فارسی، انگلیسی

جوایز و افتخارات:
بهترین سخنران جوان: در 22امین کنگره سالانه پزشکی هسته ای ایران
بهترین سخنران جوان: در 23امین کنگره سالانه پزشکی هسته ای ایران